Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brett P Monia

Showing results (51-60 of 147) with videos related to

Pageof 15
Sort By:
The Journal of Clinical Investigation|July 16, 2004
Role of resistin in diet-induced hepatic insulin resistanceEvan D Muse, Silvana Obici, Sanjay Bhanot, et al.
International Journal of Cancer|April 12, 2002
Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapyElisabeth Heere-Ress, Christiane Thallinger, Trevor Lucas, et al.
Nature Structural & Molecular Biology|July 8, 2008
Antisense transcripts are targets for activating small RNAsJacob C Schwartz, Scott T Younger, Ngoc-Bich Nguyen, et al.
Journal of Medicinal Chemistry|April 11, 2008
Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotidesThazha P Prakash, Andrew M Kawasaki, Edward V Wancewicz, et al.
Rare Diseases (Austin, Tex.)|July 24, 2014
Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung diseaseShuling Guo, Sheri L Booten, Andrew Watt, et al.
The New England Journal of Medicine|December 9, 2014
Factor XI antisense oligonucleotide for prevention of venous thrombosisHarry R Büller, Claudette Bethune, Sanjay Bhanot, et al.
Nucleic Acid Therapeutics|August 25, 2020
Immunogenicity Assessment of Inotersen, a 2'-<i>O</i>-(2-Methoxyethyl) Antisense Oligonucleotide in Animals and Humans: Effect on Pharmacokinetics, Pharmacodynamics, and SafetyRosie Z Yu, Yanfeng Wang, Dan A Norris, et al.
Metabolism: Clinical and Experimental|July 1, 2005
Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic miceYin Liang, Melville C Osborne, Brett P Monia, et al.
Molecular Vision|September 1, 2017
Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotideTamar R Grossman, Michele Carrer, Lijiang Shen, et al.
Advances in Therapy|January 23, 2023
TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron HomeostasisTomas Ganz, Elizabeta Nemeth, Stefano Rivella, et al.
Pageof 15

Showing results (51-60 of 147) with videos related to

Sort By:
Pageof 15
The Journal of Clinical Investigation|July 16, 2004
Role of resistin in diet-induced hepatic insulin resistanceEvan D Muse, Silvana Obici, Sanjay Bhanot, et al.
International Journal of Cancer|April 12, 2002
Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapyElisabeth Heere-Ress, Christiane Thallinger, Trevor Lucas, et al.
Nature Structural & Molecular Biology|July 8, 2008
Antisense transcripts are targets for activating small RNAsJacob C Schwartz, Scott T Younger, Ngoc-Bich Nguyen, et al.
Journal of Medicinal Chemistry|April 11, 2008
Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotidesThazha P Prakash, Andrew M Kawasaki, Edward V Wancewicz, et al.
Rare Diseases (Austin, Tex.)|July 24, 2014
Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung diseaseShuling Guo, Sheri L Booten, Andrew Watt, et al.
The New England Journal of Medicine|December 9, 2014
Factor XI antisense oligonucleotide for prevention of venous thrombosisHarry R Büller, Claudette Bethune, Sanjay Bhanot, et al.
Nucleic Acid Therapeutics|August 25, 2020
Immunogenicity Assessment of Inotersen, a 2'-<i>O</i>-(2-Methoxyethyl) Antisense Oligonucleotide in Animals and Humans: Effect on Pharmacokinetics, Pharmacodynamics, and SafetyRosie Z Yu, Yanfeng Wang, Dan A Norris, et al.
Metabolism: Clinical and Experimental|July 1, 2005
Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic miceYin Liang, Melville C Osborne, Brett P Monia, et al.
Molecular Vision|September 1, 2017
Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotideTamar R Grossman, Michele Carrer, Lijiang Shen, et al.
Advances in Therapy|January 23, 2023
TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron HomeostasisTomas Ganz, Elizabeta Nemeth, Stefano Rivella, et al.
Pageof 15